同型半胱氨酸血清水平作为伴门静脉血栓形成的肝细胞癌的预后标志物。

Homocysteine Serum Levels as Prognostic Marker of Hepatocellular Carcinoma with Portal Vein Thrombosis.

机构信息

Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, 95123 Catania, Italy.

Department of Biomedical and Biotechnological Science, University of Catania, Catania 95123, Italy.

出版信息

Curr Mol Med. 2019;19(7):532-538. doi: 10.2174/1566524019666190610120416.

DOI:10.2174/1566524019666190610120416

PMID:31187711

Abstract

BACKGROUND

Portal vein thrombosis (PVT) is a common complication of endstage hepatocellular carcinoma (HCC). The aim of our study was to evaluate the role of Homocysteine (Hcy) in HCC patient with PVT. Hcy is a sulphur amino-acid involved in two pathways, trans-sulphuration and remethylation, that involve vitamins B6, B12 and folates.

METHODS

We recruited 54 patients with HCC and PVT, 60 patients with HCC and without PVT and 60 control subjects. We measured serum levels of Hcy, folate, vitamins B6 and B12.

RESULTS

The comparison between HCC patients with PVT versus HCC without PVT was shown that mean values of Hcy were 6.4 nmol/L (p<0.0073) higher, LDL cholesterol were 4.8 mg/dl (p<0.0079) lower, vitamin B6 were 4.6 nmol/L(p=0.0544) lower, vitamins B 12 were 22.1 pg/ml (p=0.0001) lower.

CONCLUSION

High serum levels of Hcy are an established thrombotic risk factor in the general population. We found significantly higher levels of Hcy in HCC patients with PVT versus both HCC patients without PVT and controls.

摘要

背景

门静脉血栓形成（PVT）是终末期肝细胞癌（HCC）的常见并发症。我们研究的目的是评估同型半胱氨酸（Hcy）在 HCC 合并 PVT 患者中的作用。Hcy 是一种含硫氨基酸，参与两条途径，即转硫途径和再甲基化途径，涉及维生素 B6、B12 和叶酸。

方法

我们招募了 54 例 HCC 合并 PVT 患者、60 例 HCC 无 PVT 患者和 60 例对照。我们测量了血清 Hcy、叶酸、维生素 B6 和 B12 的水平。

结果

HCC 合并 PVT 患者与 HCC 无 PVT 患者的比较显示，Hcy 的平均值高 6.4 nmol/L（p<0.0073），LDL 胆固醇低 4.8 mg/dl（p<0.0079），维生素 B6 低 4.6 nmol/L（p=0.0544），维生素 B12 低 22.1 pg/ml（p=0.0001）。